We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+7.52%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$295M
AUM Growth
+$5.64M
(+2%)
Cap. Flow
-$9.63M
Cap. Flow
% of AUM
-3.27%
Top 10 Holdings %
Top 10 Hldgs %
99.13%
Holding
14
New
2
Increased
3
Reduced
8
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enanta Pharmaceuticals
ENTA
|
+$3.76M |
| 2 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
+$2.92M |
| 3 |
Travere Therapeutics
TVTX
|
+$2.76M |
| 4 |
Alkermes
ALKS
|
+$1.37M |
| 5 |
NextCure
NXTC
|
+$6.45K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$12.4M |
| 2 |
United Therapeutics
UTHR
|
+$5.66M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.06M |
| 4 |
AnaptysBio
ANAB
|
+$355K |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$301K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$78.5B
| $45.9M | 15.57% |
82,104
-594
| -0.7% | -$301K |
|
|
2
Alkermes
ALKS
$8.22B
| $41.4M | 14.06% |
1,688,841
+61,518
| +4% | +$1.37M |
|
|
3
Enanta Pharmaceuticals
ENTA
$366M
| $41.4M | 14.04% |
939,650
+76,802
| +9% | +$3.76M |
|
|
4
United Therapeutics
UTHR
$25.8B
| $39.4M | 13.38% |
219,690
-29,731
| -12% | -$5.66M |
|
|
TARO
5
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $39.1M | 13.28% |
543,705
-3,934
| -0.7% | -$289K |
|
|
6
Biogen
BIIB
$30B
| $33.8M | 11.46% |
97,523
-40,995
| -30% | -$12.4M |
|
7
McKesson
MCK
$100B
| $31.8M | 10.81% |
166,436
-1,204
| -0.7% | -$233K |
|
|
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $8.9M | 3.02% |
213,436
-1,544
| -0.7% | -$79.1K |
|
|
IVC
9
DELISTED
Invacare Corporation
IVC
| $7.28M | 2.47% |
901,712
-6,524
| -0.7% | -$54.3K |
|
|
EGRX
10
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $3.03M | 1.03% |
+70,804
| New | +$2.92M |
|
|
11
Travere Therapeutics
TVTX
$5.2B
| $2.04M | 0.69% |
+140,000
| New | +$2.76M |
|
|
12
AnaptysBio
ANAB
$1.58B
| $282K | 0.1% |
10,890
-14,800
| -58% | -$355K |
|
|
13
NextCure
NXTC
$16.8M
| $252K | 0.09% |
2,613
+63
| +2% | +$6.45K |
|
|
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-6,912
| Closed | -$1.06M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q2 2021 Portfolio in Review
As of Q2 2021, Krensavage Asset Management held 14 positions worth $295M, up 2% from $289M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Krensavage Asset Management withdrew a net $9.63M in Q2 2021, closing 1 position and reducing 8 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $1.06M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier.
Against the trend, Krensavage Asset Management opened a new position in Eagle Pharmaceuticals, Inc. worth $3.03M.
- Krensavage Asset Management's largest Q2 2021 buy was Eagle Pharmaceuticals, Inc.: 70,804 shares worth $3.03M.
- Krensavage Asset Management added most to Enanta Pharmaceuticals in Q2 2021, an estimated $3.76M increase.
- Krensavage Asset Management's biggest Q2 2021 reduction was Biogen, cutting an estimated $12.4M.
- Krensavage Asset Management fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $1.06M.
- Krensavage Asset Management's ten largest holdings make up 99% of its $295M portfolio in Q2 2021.
- Krensavage Asset Management opened 2 new positions and closed 1 in Q2 2021.
- Krensavage Asset Management's portfolio value rose 2% quarter-over-quarter to $295M.
Based on Krensavage Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.